RADIOGENIX SYSTEM
Clinical safety rating: caution
Comprehensive clinical and safety monograph for RADIOGENIX SYSTEM (RADIOGENIX SYSTEM).
RADIOGENIX SYSTEM is a radiopharmaceutical that emits beta radiation (yttrium-90 microspheres) to deliver targeted radiotherapy to hepatic tumors via intra-arterial administration, causing irreversible DNA damage and cell death.
| Metabolism | Yttrium-90 decays via beta emission to stable zirconium-90; not metabolized by the liver; primarily eliminated via physical decay with a half-life of 64.1 hours. |
| Excretion | Primarily renal excretion; >95% of administered activity excreted in urine within 24 hours; negligible biliary or fecal elimination. |
| Half-life | Physical half-life of 6.0 hours for Tc-99m; effective half-life is approximately 6.0 hours due to rapid renal clearance. |
| Protein binding | Approximately 30% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | Vd approximately 0.3 L/kg, indicating distribution primarily in extracellular fluid; clinical significance: rapid equilibration with interstitial space. |
| Bioavailability | 100% following intravenous administration; not administered via other routes. |
| Onset of Action | Rapid uptake by target tissues (e.g., bone, liver) within minutes; clinical imaging optimal at 2–4 hours post-injection. |
| Duration of Action | Imaging window of 2–6 hours post-injection; after 24 hours, activity is minimal; duration limited by radioactive decay. |
Not applicable; the RADIOGENIX SYSTEM is a medical imaging device, not a pharmacologic agent. No standard dosing.
| Dosage form | SOLUTION |
| Renal impairment | Not applicable. |
| Liver impairment | Not applicable. |
| Pediatric use | Not applicable. |
| Geriatric use | Not applicable. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for RADIOGENIX SYSTEM (RADIOGENIX SYSTEM).
| Breastfeeding | Contraindicated. Radioactive iodine crosses into breast milk with M/P ratio ~1.5. May cause neonatal hypothyroidism and radiation exposure. Discontinue breastfeeding. Pump and discard milk for at least 4 weeks post-treatment. |
| Teratogenic Risk | Category D: Positive evidence of human fetal risk. First trimester: radioisotope exposure may cause fetal malformations. Second and third trimesters: increased risk of fetal hypothyroidism and growth restriction. Use only if needed for maternal life-threatening conditions. |
■ FDA Black Box Warning
Radiation-induced liver disease (RILD) may occur; do not use in patients with severely compromised liver function or with high tumor burden replacing >50% of liver volume; contraindicated for patients with elevated bilirubin >2 mg/dL due to increased risk of RILD.
| Serious Effects |
Severe liver dysfunction (e.g., Child-Pugh class C); elevated total bilirubin >2 mg/dL; >50% tumor replacement of liver volume; significant extrahepatic shunting to gastrointestinal tract or lungs (lung shunt fraction >20%); active hepatitis or coagulopathy; pregnancy; prior external beam radiotherapy to liver.
| Precautions | Radiation exposure risk to personnel and environment; risk of extrahepatic deposition (e.g., gastrointestinal, pulmonary) leading to ulceration or pneumonitis; post-embolization syndrome (fever, pain, nausea); monitor liver function tests; caution in patients with impaired hepatic reserve or prior radiotherapy. |
Loading safety data…
| Fetal Monitoring |
| Baseline and serial fetal ultrasound; fetal heart rate monitoring; neonatal thyroid function tests (TSH, T4) at birth and 2 weeks; maternal thyroid function monitoring. |
| Fertility Effects | May cause transient or permanent ovarian failure (dose-dependent). Male fertility: possible oligospermia or azoospermia. Risk of genetic mutations in germ cells. Contraception recommended for 6–12 months post-therapy. |